Royalty Pharma plc and Johnson & Johnson have entered into a $500 million research and development co‑funding agreement to advance the investigational antibody JNJ‑4804, a dual‑target therapy that blocks interleukin‑23 and tumor necrosis factor pathways for chronic autoimmune diseases. The partnership will provide $250 million in 2026 and $250 million in 2027, and will give Royalty Pharma a stake in future royalties if the product receives market approval.
The co‑funding arrangement expands Royalty Pharma’s portfolio of development‑stage candidates and positions the company to capture upside from a potentially high‑margin autoimmune therapy. In return, Johnson & Johnson gains early access to Royalty Pharma’s synthetic‑royalty financing model and a share of future sales, extending the company’s reach into a new therapeutic area.
Pablo Legorreta, CEO of Royalty Pharma, said, "We are delighted to collaborate with Johnson & Johnson on the clinical development of JNJ‑4804." He added that Royalty Pharma has a strong track record of investing in immunology, beginning with early disease‑modifying biologics including TNF inhibitors, and that Johnson & Johnson is a recognized leader in immunology and believes JNJ‑4804 holds substantial promise for patients with chronic immune‑mediated diseases.
The market reacted positively to the announcement, reflecting confidence in the strategic partnership and the potential upside of the dual‑target antibody in Phase‑2 studies for ulcerative colitis, psoriatic arthritis and Crohn’s disease.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.